These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 16549195)

  • 41. Posttransplant lymphoproliferative disease: a series of 23 cases.
    Martín-Gómez MA; Peña M; Cabello M; Burgos D; Gutierrez C; Sola E; Acedo C; Bailén A; Gonzalez-Molina M
    Transplant Proc; 2006 Oct; 38(8):2448-50. PubMed ID: 17097963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L; Linde A; Falk KI
    Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
    Birkeland SA; Hamilton-Dutoit S
    Transplantation; 2003 Sep; 76(6):984-8. PubMed ID: 14508366
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of lymphoproliferative disease after liver transplantation.
    Marqués E; Jiménez C; Manrique A; Vallejo GH; Clemares M; Ortega P; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2988-9. PubMed ID: 19010169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience.
    Micallef IN; Chhanabhai M; Gascoyne RD; Shepherd JD; Fung HC; Nantel SH; Toze CL; Klingemann HG; Sutherland HJ; Hogge DE; Nevill TJ; Le A; Barnett MJ
    Bone Marrow Transplant; 1998 Nov; 22(10):981-7. PubMed ID: 9849695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma.
    Opelz G; Daniel V; Naujokat C; Döhler B
    Transplantation; 2009 Oct; 88(8):962-7. PubMed ID: 19855238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
    Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
    Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Post-liver transplantation lymphoproliferative disorders with and without infusions of donor bone marrow cells.
    Restrepo A; Albrecht F; Raez LE; Fernandez HF; Nassiri M; Byrne G; Cassileth PA
    Crit Rev Oncog; 1999; 10(3):239-45. PubMed ID: 10468183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction.
    Benden C; Aurora P; Burch M; Cubitt D; Lloyd C; Whitmore P; Neligan SL; Elliott MJ
    J Heart Lung Transplant; 2005 Dec; 24(12):2103-8. PubMed ID: 16364857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
    Ahmad I; Cau NV; Kwan J; Maaroufi Y; Meuleman N; Aoun M; Lewalle P; Martiat P; Crokaert F; Bron D
    Transplantation; 2009 Apr; 87(8):1240-5. PubMed ID: 19384173
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
    Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
    J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
    Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience.
    Buell JF; Gross TG; Hanaway MJ; Trofe J; Muthiak C; First MR; Alloway RR; Woodle ES
    Transplant Proc; 2005 Mar; 37(2):956-7. PubMed ID: 15848588
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series.
    Avolio AW; Agnes S; Barbarino R; Magalini SC; Frongillo F; Pagano L; Larocca LM; Pompili M; Caira M; Sollazzi L; Castagneto M
    Transplant Proc; 2007; 39(6):1956-60. PubMed ID: 17692665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
    Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C.
    McLaughlin K; Wajstaub S; Marotta P; Adams P; Grant DR; Wall WJ; Jevnikar AM; Rizkalla KS
    Liver Transpl; 2000 Sep; 6(5):570-4. PubMed ID: 10980055
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lymphoproliferative disorders and hematologic malignancies following organ transplantation.
    Ferry JA; Jacobson JO; Conti D; Delmonico F; Harris NL
    Mod Pathol; 1989 Nov; 2(6):583-92. PubMed ID: 2587566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study.
    Lo RC; Chan SC; Chan KL; Chiang AK; Lo CM; Ng IO
    J Clin Pathol; 2013 May; 66(5):392-8. PubMed ID: 23423516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.